Protocol Ledger

NCT04324463 · Phase III · COMPLETED

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial

Interventional Phase III clinical trial protocol NCT04324463 sponsored by Population Health Research Institute in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-04-21 Enrollment: 6,667 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04324463
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)6,667 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04324463
Protocol FieldVerified Registry Value
NCT IdentifierNCT04324463
Consolidated Lead SponsorPopulation Health Research Institute
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment6,667 participants (ACTUAL)
Registered Start Date2020-04-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04324463
Hospital Research SiteLocationSite Profile
London Health Sciences CentreLondon, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI